Medical Researches
Possibly Effective
Based on 32 Researches
DHA and EPA mitigate epileptic depressionDHA and EPA Alleviate Epileptic Depression in PTZ-Treated Young Mice Model by Inhibiting Neuroinflammation through Regulating Microglial M2 Polarization and Improving Mitochondrial Metabolism.
Study highlights EPA's effectiveness
We explored the effects of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) on depression associated with epilepsy in young mice. Using a well-structured approach, we treated three-week-old mice with a diet rich in either DHA or EPA for 21 days, followed by a series of pentylenetetrazole (PTZ) injections to induce depressive symptoms.
Our findings revealed that EPA was particularly effective in alleviating these symptoms compared to DHA. Both fatty acids significantly reduced neuronal damage in the hippocampus and improved myelin integrity, indicating potential protective effects on brain health.
Delving deeper, we discovered that DHA and EPA reduced neuroinflammation by helping microglial cells switch to a protective M2 phenotype. Moreover, both compounds lowered oxidative stress levels and enhanced mitochondrial function, which plays a crucial role in energy production and overall cellular health.
These results suggest that incorporating DHA and EPA into the diet may serve as an effective strategy to combat depression in children dealing with epilepsy, with EPA emerging as the more beneficial option.
Read More
DHA and EPA improve cognitive deficitsA Compared Study of Eicosapentaenoic Acid and Docosahexaenoic Acid in Improving Seizure-Induced Cognitive Deficiency in a Pentylenetetrazol-Kindling Young Mice Model.
Direct relevance to epilepsy treatment
We set out to explore how docosahexaenoic acid (DHA) might improve cognitive challenges associated with epilepsy, particularly in young mice experiencing seizures. Using a rodent model, we compared the effects of both DHA and eicosapentaenoic acid (EPA) on cognitive impairment induced by seizures caused by pentylenetetrazol (PTZ).
Over 21 days, mice were given diets enriched with either DHA or EPA and then subjected to PTZ treatment. Our findings revealed that both fatty acids showed potential in easing seizure-related cognitive issues, though EPA seemed to work even better in this context.
Upon further investigation, we found that both DHA and EPA helped restore certain brain chemicals and appeared to reduce ferroptosis—a process linked to cell death and involved in cognitive decline following seizures. They did this by stabilizing iron levels and decreasing harmful substances in the brain. Especially notable was how EPA outperformed DHA in fixing iron imbalances, likely thanks to its stronger influence on a specific signaling pathway.
Read More
DHA shows promise for epilepsyEffects of high-dose docosahexaenoic acid supplementation as an add-on therapy for canine idiopathic epilepsy: A pilot study.
Significant reduction in seizures
We explored the potential effects of high-dose docosahexaenoic acid (DHA) on dogs suffering from idiopathic epilepsy in a pilot study. This open-label clinical trial involved six dogs, all diagnosed with epilepsy and experiencing between 5 to 45 seizures in the month before starting DHA supplementation. The dogs were administered DHA at doses ranging from 69-166 mg/kg/day, while continuing their existing treatments.
After a period of observation, we observed that four out of the six dogs completed the full 6-month study. Notably, all the dogs showed at least a 50% reduction in seizure frequency within 2 to 3 months. By the end of the study, three dogs managed to reduce their seizures to just 0-1 per month. Importantly, we did not find any significant adverse effects in the dogs' overall health or blood tests, suggesting that this treatment was safe.
While the sample size is small and lacks control groups, the data provides promising insights into the potential of DHA as an adjunct therapy for canine idiopathic epilepsy. Our findings encourage further research but indicate that there may be a role for DHA in managing seizure frequency in dogs.
Read More
ALA reduces seizures in zebrafishEarly α-linolenic acid exposure to embryo reduces pentylenetetrazol-induced seizures in zebrafish larva.
Relevant to omega-3 epilepsy research
We explored how early exposure to alpha-linolenic acid (ALA), an essential omega-3 fatty acid, influences susceptibility to seizures in zebrafish, which serve as a valuable model for studying epilepsy. Healthy zebrafish embryos were incubated in water with different concentrations of ALA before being tested for their response to pentylenetetrazol (PTZ), a chemical known to induce seizures.
At concentrations of 10 µM and 20 µM, we observed a notable reduction in seizure-like behaviors among the larvae. This was indicated by a decrease in how far and how fast they moved during the seizures. Additionally, treated larvae displayed longer times before experiencing full-blown clonus-like seizures.
We also found lower levels of c-fos mRNA, which suggests reduced neuronal activation linked to seizure activity. Interestingly, higher concentrations of ALA led to increased levels of both ALA and docosahexaenoic acid (DHA) in the zebrafish. Overall, our study showed that early exposure to ALA effectively reduces PTZ-induced seizures in zebrafish larvae, highlighting its potential role in managing epilepsy.
Read More
We focused on understanding how specialized lipids derived from docosahexaenoic acid (DHA) influence epilepsy, particularly looking into a compound known as protectin D1. Through a study with a mouse model of epilepsy, we found that inflammation in the brain is a significant contributor to seizures.
Our research showed that during a critical period when seizures were expected to start, the processes that help resolve inflammation were activated but delayed compared to the inflammatory response itself. We measured levels of various inflammatory markers and the genes involved in resolving inflammation, revealing that these protective pathways had not been properly engaged in the context of developing epilepsy.
Notably, we found that injecting protectin D1 into the brains of mice reduced the levels of harmful inflammatory markers and led to significant improvements in their recovery. The treated mice not only regained weight but also demonstrated better cognitive function and showed a substantial reduction in both the frequency and duration of their seizures.
This suggests that boosting the body's natural resolution processes could offer new therapeutic options for epilepsy, highlighting that current treatments primarily manage symptoms rather than address the underlying problem.
Read More
User Reviews
EXCELLENT OMEGA AND THE PRICE IS VERY reasonable. I take omega due to severe epilepsy, which leads to dementia, and it significantly alleviates my condition.
Ensure you buy; you won’t regret it! It's fantastic for a reasonable price. I take it for epilepsy and feel considerable relief. My housemates also take it, as we all miss omega-rich foods.
Docosahexaenoic acid is essential for the brain, enhancing concentration and memory while reducing seizure frequency in epilepsy.
DHA, a docosahexaenoic fatty acid in Omega-3, is crucial for brain health and may reduce seizures in epilepsy by up to 30%. A very economical package for an adequate price; I take one capsule daily.